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Summary. — Computer simulations have become a widely used and powerful tool
to study the behaviour of many-particle and many-interaction systems and processes
such as nucleic acid dynamics, drug-DNA interactions, enzymatic processes, mem-
brane, antibiotics. The increased reliability of computational techniques has made
possible to plane a bottom-up approach in drug design, i.e. designing molecules
with improved properties starting from the knowledge of the molecular mechanisms.
However, the in silico techniques have to face the fact that the number of degrees of
freedom involved in biological systems is very large while the time scale of several
biological processes is not accessible to standard simulations. Algorithms and meth-
ods have been developed and are still under construction to bridge these gaps. Here
we review the activities of our group focussed on the time-scale bottleneck and, in
particular, on the use of the metadynamics scheme that allows the investigation of
rare events in reasonable computer time without reducing the accuracy of the cal-
culation. In particular, we have devoted particular attention to the characterization
at microscopic level of translocation of antibiotics through membrane pores, aiming
at the identification of structural and dynamical features helpful for a rational drug
design.
PACS 87.15.A- – Theory, modeling, and computer simulation.
PACS 87.16.dp – Transport, including channels, pores, and lateral diffusion.
1. – Introduction
Several alarming features indicate that the strategy to develop new drugs should be
revised and reconsidered. An example is the problem of the bacterial resistance to antibi-
otics. In the second half of the last century, infectious diseases caused by bacteria seemed
to be definitely defeated because of the timely production of efficient antibacterial drugs.
This picture went hand in hand with a progressive decrease of investment and research
within the pharmaceutical industry. However, bacteria have been able to develop sev-
eral mechanisms of resistance that acting simultaneously make the use of any antibiotics
weak or ineffective. This phenomenon is known as bacterial multidrug resistance (MDR)
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and is responsible for more deaths from infection, longer hospital stays and an increase
of more toxic and expensive drugs [1, 2]. The spread of MDR bacteria and re-emerging
pathogens, both in hospitals and in the community, appears in a moment where no truly
novel active antibacterial compounds are in clinical trials, that means no new drugs for
at least 6/8 years [3]. Today to respond to the emergency call of new drugs we need to
strongly reinforce antibacterial research and reinvent a new way to search drugs [4, 5],
moving from the traditional screening on large amount of molecules to a rational and
microscopically well-founded drug design. A key role in development of this bottom-up
strategy can be played by computer simulations and, in particular, by Molecular Dy-
namics (MD) simulations [6]. This technique has the potentiality to provide detailed
information, i.e., at the microscopic scale, regarding the structure, dynamics and ener-
getics of the system of interest. All the mentioned properties, often barely detectable
in experiments, represent a necessary starting point for the rational strategy that can
rescue drug design from a dangerous stalemate. However, typical MD simulations have
to face very often limitations associated with the reduced time and size scales (∼ 100 ns
and ∼ 100000 atoms) of the systems that are simulated. Several algorithms have been
developed to tackle these limits, and promising results have been obtained in the study
of biological problems. In our group we have concentrated our attention on the time
bottleneck, using metadynamics [7], a technique that allows the investigation of rare
events (see sect. 2). Recently, metadynamics has been successfully used to investigate
various biology-oriented problems (see refs. [8-14] for some examples), but in the present
paper we will briefly overview only some results obtained in our group concerning the
translocation of antibiotics through bacterial pores.
2. – Metadynamics
Standard MD simulations cannot afford the typical biological time scale without im-
portant approximations in the system. Either the system is described at a lower level, the
so-called coarse-grained description, or one can drastically approximate the interaction
energies, producing systematic errors. However, to provide insights into biology-oriented
questions often the system cannot be handled at the approximate levels mentioned above
but must be treated at an all-atom level. Among the different methods proposed to ac-
celerate simulations [15-25], the metadynamics [7, 26] seems extremely powerful. The
algorithm requires that the process under investigation can be represented using a small
set of reaction coordinates, called also collective variables (CVs), to be defined a priori
and be process-dependent. When the slow evolution of the process can be attributed
principally to these few CVs, the artifice is to accelerate the time evolution of the CVs.
During standard MD simulations many conformations of the same free-energy min-
imum are sampled, but the same conformer can be visited many times, i.e., memory
effects are absent. The idea of metadynamics is to take advantage of the previously
visited conformers, moving from an algorithm with zero-memory effects to a history-
dependent algorithm, the so-called non-Markovian dynamics. Within metadynamics,
only the defined CVs are forced to evolve with a non-Markovian dynamics, during the
simulation adding with a given frequency penalty terms in order to avoid, or to penalize,
if the same conformer is visited many times. All the other coordinates are maintained
near equilibrium. With this scheme it is possible, in the range of a typical simulation
(tens of nanoseconds), to observe a process whose time scale is several microseconds. The
core of metadynamics is to identify a priori the few CVs that better describe the process
under investigation at the microscopic scale. They are complex functions of selected
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Fig. 1. – (Colour online) (A) Top view of the OmpF structure with the key charged residues
of the constriction zone highlighted and labeled (Arg-42-82-132, Lys-16 in blue and Glu-117,
Asp-113 in red); (B) side view of OmpF; (C) structure of ampicillin. The central four-members
ring is the active part that binds to the bacterial target, the peptidoglycan.
degrees of freedom, such as a geometrical coordinate (distances, angles, dihedrals) or an
interactions-based coordinate, such as the coordination number of a group of atoms, the
number of hydrogen bonds, or hydrophobic contacts between different groups. The first
advantage of metadynamics is the capability to accelerate events. However, the choice
of the CVs represents implicitly a way to test whether that process can be described
by those CVs, or implicitly it is assumed as a mechanism for that process. In the case
of their failure, any evolution of the system can be observed, and more appropriate co-
ordinates should be considered, or a different mechanism should be assumed for that
process. Therefore, the procedure is implicitly a speculation on the mechanism govern-
ing the process. Another advantage of this algorithm is the possibility to quantify the
process through a free-energy description [26]. Finally, with respect to other acceleration
algorithms metadynamics does not require to define the range of variation of the CVs a
priori or the predefined grid, instead letting the system evolve toward the lowest transi-
tion state, thus obtaining the minimum free-energy landscape along the path connecting
the two minima. This prevents sampling of uninteresting regions and, in principle, allows
the introduction of a high number of CVs [12].
3. – Translocation of antibiotics
Our investigation strategy was based on the use of metadynamics to find a reactive
path for the escape of ampicillin down from the constriction region of OmpF [27]. OmpF
is considered one of the main entry points for different classes of antibiotics to pass
through the outer membrane and is a trimeric porin with 16 beta-barrels that also shows
a small cation selectivity, with each monomer charged at −10 at neutral pH (see fig. 1
A and B). The high-resolution double-funnel-shape crystal structure of OmpF [28] is
characterized by a narrow central region created by the internal fold of loop L3, the
longest in OmpF. This region, whose sizes are roughly 7 × 11 A˚, is supposed to be the
bottleneck for transport properties, as the loop L3 prevents the passage of large molecules.
The starting structure for ampicillin in the constriction region essentially coincides with
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Fig. 2. – The free energy surface associated with the reaction pathway along the subspace of the
two variables, displacement of the center of mass of moxifloxacin along the z-axis of the porin
(z = 0 corresponds to the constriction zone), and orientation angle. Each isoline corresponds to
1 kcal/mol.
the one proposed by Bezrukov and co-workers [29]. As stated above, metadynamics has
allowed considering in a natural and not computer-time–demanding way more than one
relevant coordinate for the process. The coordinates we assume to be accelerated in our
simulations are inspired by the analysis of the initial structure. Since the orientation of
the compound with respect to the translocation axis has to be appropriate to facilitate
the passage, the angle between the axis of the molecule and the pore axis represents
one rate-limiting slow coordinate for the translocation and hence is a natural collective
variable to consider and to accelerate. The second natural coordinate is the position
of the ampicillin along the z-axis of diffusion, which must change in order to observe
translocation. Accelerated MD simulations proved the passage of ampicillin through the
constriction region with a simulation lasting a few nanoseconds. The obtained free energy
surface is reported in fig. 2. The main results obtained can be cast in four points:
– During translocation, no large conformational change of the pore is observed. In
particular, the constriction zone keeps its structure practically unaffected by the
presence of the antibiotic.
– The barrier encountered by ampicillin in exiting from the binding-site is on the
order of 10/12 kcal/mol. Using the transition state theory, this corresponds to a
typical time of hundreds of microseconds, which agrees well with experiments.
– The flexibility of the molecule seems to help translocation through the central
region. The same simulation performed with an internal dihedral angle of ampi-
cillin constrained to a fixed value yielded still a translocation but with a higher
energy barrier to be overcome. It is tempting to postulate, therefore, that the low
permeability of OmpF toward other compounds of larger size, like azlocillin and
piperacillin, probably originates from their bulky lateral chains.
– The charged residues are important in locations other than near the constriction
region, as for example the role of Lys-16, located on the opposite side across the
DRUG DESIGN: INSIGHTS FROM ATOMISTIC SIMULATIONS 71
pore, in the so-called anti-loop 3, in the escape process via an interaction with the
COO group of the antibiotic. The fingerprints of this role confirmed the experi-
mental findings of an altered permeability of the pore as a consequence of mutation
of the Lys-16 residue [30,31].
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